# Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

> **NCT04348006** · PHASE4 · WITHDRAWN · sponsor: **Al-Rasheed University College**

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib 3.5 MG

## Key facts

- **NCT ID:** NCT04348006
- **Lead sponsor:** Al-Rasheed University College
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-01
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled in the study
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348006, "Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04348006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*